Last year, a study entitled “T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension” published in the Chest journal associated the increased activity of a T-cell-mediated immune process — the T-helper 17 pathway — with Pulmonary Arterial Hypertension (PAH). This research is now being contested by a group of researchers…
News
In a world where vasodilators rule the landscape of treatments for pulmonary arterial hypertension (PAH), scientific research groups and pharmaceutical companies around the world are working to develop targeted therapeutics that focus on specific cellular pathways that are associated with dysfunction in PAH patients. Within the realm of targeted therapeutics,…
Researchers at the Yale Cardiovascular Research Center have identified a specialized cell type involved in pulmonary hypertension pathogenesis. The research paper, entitled “Smooth muscle cell progenitors are primed to muscularize in pulmonary hypertension,” was published in Science Translational Medicine. Pulmonary hypertension (PH) is a life-threatening…
October 13 is World Thrombosis Day, an event that increases global awareness and focuses attention on the often overlooked and misunderstood disease of thrombosis as an urgent and growing health problem. In recognition of World Thrombosis Day and the seriousness and prevalence of venous thromboembolism (VTE), the Montreal,…
Non-invasive techniques to detect pulmonary hypertension in individuals who are at a high risk for developing the disease are in high demand to enable more patients to be diagnosed and treated in the early stages. As the gold standard, right heart catheterization has been the primary mode of detecting an increase…
Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Letairis® (ambrisentan) with tadalafil for pulmonary arterial hypertension (PAH) to diminish disease progression risk and hospitalization and to improve the ability to exercise — a decision that directly follows recent study results indicating the…
In a recent study titled, “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension,” published in the New England Journal of Medicine, a global team of researchers demonstrated that treatment combining ambrisentan and tadalafil significantly improves the clinical condition of pulmonary arterial hypertension patients.
Promising, new data from a clinical trial of Bellerophon Therapeutics’ product candidate developed under the INOpulse® program targeting pulmonary hypertension was recently presented at the European Respiratory Society (ERS) International Congress 2015. The results could eventually lead to an approved therapy for Pulmonary Hypertension associated with COPD. Pulmonary hypertension is characterized by…
North Bergen, New Jersey locals Carlos Torres and Martha Gonzalez reported in a recent press release that they felt “extremely blessed” upon witnessing Pope Francis kiss their 9-year-old son, Daniel, during His Holiness’ New York City visit, believing that the Pope’s blessing may help Daniel fight…
A recent study from Japan has shown that dividing cells involved in causing idiopathic pulmonary arterial hypertension (IPAH) may be stopped with a new type of drug called a calcilytic. The research could led to new treatments for IPAH. The study, titled “Inhibition of Excessive Cell Proliferation…
An international group of scientists has comprehensively characterized the genetics of pulmonary arterial hypertension (PAH). This new information could ultimately help clinicians treat the disease based on individual traits and genetic makeup. This is the most complete set of genetic data that has been collected about the disease to date.
Bellerophon Therapeutics recently announced that INOpulse, a type of nitric oxide that helps blood vessels expand, is effective in treating Pulmonary Arterial Hypertension (PAH) based on middle-stage data from a Phase 2 trial. The US Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA), which will help to…
